Maui Sky – Lifestyle
Author:
Oculis Holding AG
Oculis Publishes Invitation to the Annual General Meeting
April 21, 2026
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
April 20, 2026
Oculis to Participate in Upcoming Investor Conferences
April 7, 2026
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
March 31, 2026
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
March 16, 2026